Stockwatch: Already seen
This article was originally published in Scrip
Executive Summary
In theory, if you wait long enough, another Genentech will IPO, develop another Avastin, be acquired by another Roche, partially re-float and be acquired again. Strangely this week, events for other momentous drug approvals and IPOs seem to be repeating themselves but investors don't seem to be learning from their past mistakes.